NCT05686993View on ClinicalTrials.gov

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 6, 2023

Conditions
Primary AldosteronismEndocrine Hypertension
Interventions
DRUG

Cinnarizine

Cinnarizine oral 30mg TDS

DRUG

NIFEdipine ER

Nifedipine oral 60mg daily extended release

Trial Locations (1)

EC1A 7BE

St Bartholomew's Hospital, London

All Listed Sponsors
lead

Queen Mary University of London

OTHER